TY - JOUR
T1 - Beneficial effects of PJ34 and INO-1001, two novel water-soluble poly(ADP-ribose) polymerase inhibitors, on the consequences of traumatic brain injury in rat
AU - Besson, Valérie C.
AU - Zsengellér, Zsuzsanna
AU - Plotkine, Michel
AU - Szabó, Csaba
AU - Marchand-Verrecchia, Catherine
N1 - Funding Information:
This work was supported in part by a grant from the National Institutes of Health to C.S. (R44NS037985).
PY - 2005/4/18
Y1 - 2005/4/18
N2 - Traumatic brain injury produces peroxynitrite, a powerful oxidant which triggers DNA strand breaks, leading to the activation of poly(ADP-ribose) polymerase-1 (PARP-1). We previously demonstrated that 3-aminobenzamide, a PARP inhibitor, is neuroprotective in a model of traumatic brain injury induced by fluid percussion in rat, suggesting that PARP-1 could be a therapeutic target. In order to confirm this hypothesis, we investigated the effects of PJ34 and INO-1001, two PARP inhibitors from structural classes other than benzamide, on the post-traumatic consequences. Pre- and post-treatments with PJ34 (30 mg/kg/day) and INO-1001 (10 mg/kg/day) decrease the neurological deficit at 3 days post-injury and this deficit is still reduced at 7 days. These neurological recovery-promoting effects are associated with the inhibition of PARP-1 activation caused by trauma, as demonstrated by abolishment of immunostaining of poly(ADP-ribose). Thus, the present work strengthens strongly the concept that PARP-1 inhibition may be a suitable approach for the treatment of brain trauma.
AB - Traumatic brain injury produces peroxynitrite, a powerful oxidant which triggers DNA strand breaks, leading to the activation of poly(ADP-ribose) polymerase-1 (PARP-1). We previously demonstrated that 3-aminobenzamide, a PARP inhibitor, is neuroprotective in a model of traumatic brain injury induced by fluid percussion in rat, suggesting that PARP-1 could be a therapeutic target. In order to confirm this hypothesis, we investigated the effects of PJ34 and INO-1001, two PARP inhibitors from structural classes other than benzamide, on the post-traumatic consequences. Pre- and post-treatments with PJ34 (30 mg/kg/day) and INO-1001 (10 mg/kg/day) decrease the neurological deficit at 3 days post-injury and this deficit is still reduced at 7 days. These neurological recovery-promoting effects are associated with the inhibition of PARP-1 activation caused by trauma, as demonstrated by abolishment of immunostaining of poly(ADP-ribose). Thus, the present work strengthens strongly the concept that PARP-1 inhibition may be a suitable approach for the treatment of brain trauma.
KW - Inhibitors
KW - Neurological deficit
KW - Neuroprotection
KW - Poly(ADP-ribose) polymerase
KW - Rat
KW - Traumatic brain injury
UR - http://www.scopus.com/inward/record.url?scp=17044383375&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17044383375&partnerID=8YFLogxK
U2 - 10.1016/j.brainres.2005.01.096
DO - 10.1016/j.brainres.2005.01.096
M3 - Article
C2 - 15829224
AN - SCOPUS:17044383375
SN - 0006-8993
VL - 1041
SP - 149
EP - 156
JO - Brain Research
JF - Brain Research
IS - 2
ER -